Abstract

Objective
Determine if cocaine use impacts gut permeability, promotes microbial translocation and immune activation in people living with HIV (PLWH) using effective antiretroviral therapy (ART).

Methods
Cross-sectional analysis of 100 PLWH (ART ≥ 6 months, HIV-RNA < 200 copies/mL) from the Miami Adult Studies on HIV (MASH) cohort. Cocaine use was assessed by self-report, urine screen, and blood benzoylecgonine (BE). Blood samples were collected to assess gut permeability (intestinal fatty acid-binding protein, I-FABP), microbial translocation (lipopolysaccharide, LPS), immune activation (sCD14, sCD27, and sCD163) and markers of inflammation (hs-CRP, TNF-α and IL-6). Multiple linear regression models were used to analyze the relationships of cocaine use.

Results
A total of 37 cocaine users and 63 cocaine non-users were evaluated. Cocaine users had higher levels of I-FABP (7.92±0.35 vs. 7.69±0.56 pg/mL, P = 0.029) and LPS (0.76±0.24 vs. 0.54±0.27 EU/mL, P<0.001) than cocaine non-users. Cocaine use was also associated with the levels of LPS (P<0.001), I-FABP (P = 0.033), and sCD163 (P = 0.010) after adjusting for
Cocaine use was associated with markers of gut permeability, microbial translocation, and immune activation in virally suppressed PLWH. Mitigation of cocaine use may prevent further gastrointestinal damage and immune activation in PLWH.

Introduction

People living with HIV (PLWH) exhibit pathological processes that affect the gastrointestinal tract. One of the main features of infection with the human immunodeficiency virus (HIV) is the massive destruction of CD4+ T cells in the gastrointestinal tract, which are more frequently infected by HIV than those in blood, indicating the gastrointestinal tract as a major target and viral reservoir for HIV in the human body [1]. The loss and poor reconstitution of CD4+ T cells in the gastrointestinal tract promote disruption of intestinal homeostasis, mucosal regeneration, and gut integrity despite antiretroviral therapy (ART) [2–6].

Preserving the gut barrier is vital for the intestinal epithelium. When the intestinal barrier is damaged, intestinal permeability increases, allowing translocation of products including lipopolysaccharide (LPS), into the bloodstream, causing endotoxemia and inflammation [7]. I-FABP are small cytosolic proteins that transport fatty acids to the enterocytes. In the event of intestinal ischemia or gut integrity damage, I-FABP is leaked from the gut to the systemic circulation indicating intestinal barrier dysfunction and permeability [8].

The diversity of the intestinal microbiome appears to be reduced in PLWH [9–15]. The combination of reduced intestinal CD4+ T cells and alterations in the microbiome contribute to disruptions of tight junctions in the intestinal epithelium, which in turn leads to the loss of gut integrity and microbial translocation in PLWH [16]. Microbial translocation (MT) refers to the passage or transport of the microflora or its products from the gastrointestinal tract into the systemic circulation without causing bacteremia [17]. PLWH present with products of MT; specifically LPS, also known as endotoxin [18, 19]. In turn, LPS in the circulation induces immune activation and inflammation, considered hallmarks of HIV infection and predictors of poor clinical outcomes in PLWH [20–24]. Chronic immune activation has been identified as one of the factors that increase morbidity and mortality among PLWH regardless of ART use and viral suppression and [25]. In addition, constant low levels of viral replication from viral reservoirs, particularly in the gastrointestinal tract, persist despite effective ART thereby promoting chronic immune activation [26]. This creates a vicious cycle where gut barrier immunity is compromised by HIV infection, promoting microbial translocation and immune activation, which in turn contribute to HIV disease progression.

Cocaine is one of the most frequently used illicit drugs in the United States [27] and it is disproportionately used by PLWH [28]. Epidemiological studies have demonstrated that active illicit drug use, particularly cocaine, is associated with poor adherence to ART, reduced virologic and immunologic control, HIV disease progression, and mortality [29, 30]. Cocaine use poses deleterious risks related to the gastrointestinal tract, including malnutrition, anorexia, gastrointestinal bleeding, reduced blood supply to enterocytes, and...
dysbiosis of the gut microbiome among PLWH [31–33]. Also, in vitro and in vivo studies suggest that cocaine can impair gut integrity, leading to microbial translocation and systemic inflammation [34, 35]. Nonetheless, the role of cocaine use on gut permeability, microbial translocation, and immune activation among PLWH has not been thoroughly investigated and characterized. Therefore, the purpose of this study was to examine the relationships between cocaine use, gut permeability, microbial translocation, and immune activation in the context of HIV infection.

Methods
Study participants
Participants for this cross-sectional study were selected from the ongoing Miami Adult Studies in HIV (MASH) cohort, a National Institute on Drug Abuse (NIDA)-funded study examining the impact of substance use on HIV infection and comorbidities. The MASH cohort includes a large number of non-Hispanic Blacks, Hispanics, and non-injection drug users who are followed every 6 months with comprehensive surveys administered on the same day as fasting blood and urine samples are collected. Participants for this study were selected from the MASH cohort if they met the following criteria: age 21 and older; HIV infected on ART with suppressed HIV viral load (<200 copies/ml) and CD4+ T cell count >200 cells/μL for at least 6 months; and no hazardous drinking as determined by an Alcohol Use Disorders Identification Test (AUDIT) score below 8. The exclusion criteria for this study were comprised of co-infection with hepatitis B or C virus and diagnosis of an inflammatory bowel disease, confirmed with review of medical records. This study was approved by the Florida International University Institutional Review Board. All participants provided written consent for participation in the study and release of medical records.

Laboratory analyses
Blood samples were collected every 6 months as part of each MASH cohort study visit and aliquoted for storage at -80˚ for later use. Plasma samples collected at baseline were used to assess blood levels of LPS for microbial translocation, intestinal fatty-acid binding protein (I-FABP) a biomarker for gut integrity, soluble CD14 (sCD14), sCD163, and sCD27 for immune activation, and hs-CRP, TNF-α and IL-6 for inflammation. I-FABP was assessed using the Human FABP2/I-FABP Immunoassay by R&D Systems (Minneapolis, MN, USA) according to manufacturer’s instructions with a sample dilution of 1:5. LPS was measured using the Pierce Chromogenic Endotoxin Quant Kit by Thermo Fisher Scientific (Rockford, IL, USA) according to manufacturer’s instructions with the following modifications: samples were diluted 1:10 with endotoxin-free water to avoid interference with background color and preheated to 70˚C for 15 minutes prior to analyses to inactivate plasma proteins. Triplicates were assessed for each sample. Immune activation markers were measured in singlicate using the magnetic analyte-specific bead-based Luminex multiplex immunoassays (Luminex Human Discovery Assays, R&D Systems, Minneapolis, MN, USA). Soluble CD14 was assayed at a 1:200 plasma dilution, while sCD27, and sCD163 were run at 1:2. Analyte concentrations were determined by the protocol-based data acquisition software using a standard curve derived from the known reference concentration as supplied by the manufacturer. TNF-α and IL-6 were measured by using the analyte-specific bead-based Luminex multiplex immunoassays (EMD, Millipore Corporation). High-sensitivity C-reactive protein (hs-CRP), a marker of systemic inflammation, was also measured in blood (Labcorp, Burlington, NC, USA).
Substance use

Cocaine use was defined as self-reported use (in the past 30 days), a positive urine drug screen (American Bio Medica®, Kinderhook, NY, USA), or blood benzoylecgonine (BE) concentration ≥0.1 ng/mL. Cocaine is rapidly converted in the liver into its primary metabolite, BE [36]. A modified liquid chromatography with tandem mass spectrometry (LC-MS/MS) method was used to measure BE concentrations in plasma [37]. The target analyte and internal standard were identified and quantified using a triple quadrupole mass spectrometer (TSQ Quantum Ultra with a HESI-II probe, Thermo Fisher Scientific Inc., San Jose, CA, USA). Cigarette smoking and alcohol consumption (AUDIT score) was self-reported.

HIV disease progression and medication history

Markers of HIV disease progression (CD4+ T cell count and HIV viral load) were abstracted from medical records with participants’ written authorization. Use and adherence with ART was obtained from the AIDS Clinical Trials Group (ACTG) validated adherence questionnaire administered to study participants.

Statistical analyses

Descriptive statistics including means, standard deviations, and percentages were used to describe the data. Log transformations were performed for non-normally distributed continuous outcomes for I-FABP, LPS, sCD14, sCD27, sCD163, hs-CRP, TNF-α and IL-6. Independent sample T-tests (or non-parametric Wilcoxon Rank-Sum Test) were conducted to compare the distribution of continuous outcomes between cocaine users and non-users. Pearson and Spearman correlations were used to evaluate correlations between continuous variables. Multiple linear regression models were implemented to analyze the relationships of cocaine use with log-transformed I-FABP, LPS, sCD14, sCD27, sCD163, hs-CRP, TNF-α and IL-6 while controlling for covariates [age, sex, race, CD4 cell count, suppressed HIV viral load (<20 copies/mL), and cigarette smoking]. The dependent variables in the logistic regression models were I-FABP and LPS at the following cut-offs: I-FABP and LPS < or ≥ median. An alpha less than 0.05 was considered statistically significant. All statistical analyses were performed using SPSS software, version 27.

Results

Participant characteristics

A total of 100 PLWH were selected for this study, with mean age of 53.4±6.9 years (Table 1). Thirty-seven participants (37%) used cocaine. Most participants were African American (66%) and 29% were Hispanic. Participants had a mean duration of known HIV diagnosis of 17.2±7.3 years, 78% had undetectable HIV viral load (<20 copies/mL) and 22% were virally suppressed (HIV viral load 20–200 copies/mL). Participants had a mean BMI of 28.7±5.8 kg/m² and 37% were obese. Approximately twice as many cocaine users smoked cigarettes than cocaine non-users (64.9% vs. 36.5%, P = 0.006).

Correlations between biomarkers

As shown in Table 2, blood BE, the major metabolite of cocaine in blood, was directly associated with LPS (rho = 0.276, P = 0.028), sCD14 (rho = 0.274, P = 0.031), and sCD163 (rho = 0.250, P = 0.049). I-FABP only correlated with sCD27 (r = 0.221, P = 0.034) and LPS only correlated with sCD163 (r = 0.422, P < 0.001). Plasma levels of sCD14 correlated with sCD27 (r = 0.381, P < 0.001) and sCD163 (r = 0.240, P = 0.021).
Table 1. Participant’s characteristics a.

| Characteristics             | Total (N = 100) | Cocaine Non-users (N = 63) | Cocaine Users (N = 37) | P value b |
|-----------------------------|-----------------|----------------------------|------------------------|-----------|
| Age (years)                 | 53.4±6.9        | 52.8±7.4                   | 54.3±5.8               | 0.304     |
| Gender (male)               | 53.0%           | 55.6%                      | 48.7%                  | 0.504     |
| Race/Ethnicity              |                 |                            |                        |           |
| African American            | 66.0%           | 57.6%                      | 42.4%                  | 0.015     |
| Hispanic                    | 29.0%           | 33.3%                      | 21.6%                  | 0.213     |
| White                       | 28.0%           | 34.9%                      | 16.2%                  | 0.100     |
| Other                       | 6.0%            | 6.4%                       | 5.4%                   | 0.603     |
| Log_{10} HIV VL (copies/mL) | 1.75±0.33       | 1.78±0.32                  | 1.70±0.36              | 0.549     |
| Undetectable HIV VL (<20 copies/mL) | 78%            | 69.7%                      | 30.3%                  | 0.207     |
| Suppressed HIV Viral Load (20–200 copies mL) | 22%            | 54.5%                      | 45.5%                  | 0.142     |
| Duration of HIV (years)     | 17.2±7.3        | 18.0±7.2                   | 15.6±7.1               | 0.150     |
| CD4 cell count (cells/μL)   | 641.7±354.1     | 633.4±305.6                | 655.9±428.5            | 0.780     |
| Cigarette smoker            | 47.0%           | 36.5%                      | 64.9%                  | 0.006     |
| Alcohol (drinks/week)       | 2 (0, 5)        | 1 (0, 3)                   | 2 (0, 6)               | 0.284     |
| BMI (kg/m²)                 | 28.7±5.8        | 29.0±5.9                   | 28.2±5.6               | 0.520     |
| Obese                       | 37.0%           | 38.1%                      | 35.1%                  | 0.767     |
| LPS (EU/mL)                 | 0.59±0.23       | 0.53±0.24                  | 0.72±0.12              | <0.001    |
| I-FABP (pg/mL)              | 2515.83±1072.95 | 2337.56±1072.95            | 2866.97±798.06         | 0.014     |
| sCD14 (pg/mL)               | 1038.47±424.2   | 1021.81±402.55             | 1080.73±480.7          | 0.552     |
| sCD27 (pg/mL)               | 7.95±2.94       | 7.70±2.52                  | 8.58±3.81              | 0.291     |
| sCD163 (pg/mL)              | 635.71±418.52   | 613.25±431.73              | 692.74±385.01          | 0.393     |
| hs-CRP (mg/L)               | 3.70±3.57       | 3.58±3.63                  | 3.94±3.48              | 0.638     |
| TNF-α (pg/mL)               | 8.02 (5.76–11.44) | 8.31 (5.78–11.44)         | 7.48 (3.05–11.47)      | 0.445     |
| IL-6 (pg/mL)                | 0.7 (6.6–50.8)  | 24.8 (8.5–55.5)            | 4.9 (3.3–28.3)         | 0.453     |

Bold indicates statistical significance at P < 0.05.

aData are summarized as mean ± standard deviation (or median [interquartile range]) for continuous variables and No. (%) for categorical outcomes.

bBetween group comparisons consisted of T-tests (or Wilcoxon Rank-Sum Test) for continuous variables and Chi-square Tests for categorical variables.

https://doi.org/10.1371/journal.pone.0275675.t001

Table 2. Correlation matrix a.

|            | BMI          | hs-CRP b | CD4+         | I-FABP b | LPS b | sCD14 b | sCD27 b | sCD163 b | BE c |
|------------|--------------|----------|--------------|----------|-------|---------|---------|----------|------|
| Age        | -0.231**     | 0.117    | -0.084       | 0.093    | -0.047| 0.010   | 0.191   | -0.139   | 0.014|
| BMI        | -            | 0.293**  | 0.234**      | -0.186   | -0.132| 0.183   | -0.010  | 0.197    | 0.066|
| hs-CRP     | -            | -        | 0.247**      | -0.066   | -0.152| 0.061   | 0.036   | -0.057   | 0.065|
| CD4+       | -            | -        | -            | -0.022   | 0.097 | -0.058  | -0.181  | -0.093   | -0.109|
| I-FABP     | -            | -        | -            | -        | 0.123 | -0.088  | 0.221** | 0.023    | 0.133|
| LPS        | -            | -        | -            | -        | -     | -0.079  | 0.068   | -0.084   | 0.276|
| sCD14      | -            | -        | -            | -        | -     | -       | 0.381** | 0.240**  | 0.274|
| sCD27      | -            | -        | -            | -        | -     | -       | -0.377**| 0.125    | 0.250|
| sCD163     | -            | -        | -            | -        | -     | -       | -       | -        | -     |

Bold indicates statistical significance at P < 0.05.

aData for Spearman’s correlation, unless otherwise specified

bLog-transformed

cSpearman’s correlation

**P < 0.05

***P < 0.01

https://doi.org/10.1371/journal.pone.0275675.t002
Gut permeability and microbial translocation

Cocaine users had higher levels of I-FABP (2866.97 ± 798.06 vs. 2337.56 ± 1072.95 pg/mL, \( P = 0.014 \)) and LPS (0.72 ± 0.12 vs. 0.53 ± 0.24 EU/mL, \( P < 0.001 \)) than cocaine non-users, indicating greater gastrointestinal permeability and microbial translocation among the cocaine users (Fig 1). A series of multiple regression models were carried out to investigate whether cocaine use was associated with I-FABP and LPS levels in plasma, controlling for age, sex, race, CD4 cell count, suppressed HIV viral load (20–200 copies/mL), and cigarette smoking (Table 3). When adjusted for these confounders, cocaine use was significantly associated with both I-FABP (\( P = 0.033 \)) and LPS levels (<0.001) as shown in Table 3.

Logistic regression analyses indicated that cocaine use was significantly associated with high LPS levels [≥ median 0.63 (IQR:0.48–0.73) EU/mL (\( P < 0.001 \)) after controlling for the same covariate. In addition, cocaine users had 5.15 times higher odds to exhibit high LPS levels than non-users (OR: 5.15 95% CI: 1.89–13.9; \( P < 0.001 \)), as shown in Table 4. No significant association was found between cocaine use and high levels of I-FABP.

Immune activation and inflammation

T-tests showed no differences in markers of immune activation between cocaine users and non-users (Fig 1). Table 3 also shows that there were no significant associations between cocaine use and sCD14 (\( P = 0.933 \)), sCD27 (\( P = 0.587 \)) using multiple regression analyses.

![Fig 1. Comparison of gut permeability, microbial translocation, immune activation, and inflammatory markers between cocaine users and non-users. Bold indicates statistical significance at \( P < 0.05 \). Microbial translocation: a) LPS. Gut permeability: b) I-FABP. Immune activation: c) sCD14, d) sCD27, e) sCD163. Inflammation: f) hs-CRP, g) TNF-α, h) IL-6.](https://doi.org/10.1371/journal.pone.0275675.g001)
However, the association between cocaine use and sCD163 was statistically significant at $P = 0.010$ (Table 3). No significant associations were found between cocaine use and inflammatory markers hs-CRP ($P = 0.688$), TNF-$\alpha$ ($P = 0.433$) and IL-6 ($P = 0.456$) after adjusting for age, sex, race, CD4 cell count, suppressed HIV viral load (20–200 copies/mL) and cigarette smoking. However, LPS levels were significantly associated with hs-CRP ($P = 0.040$) and TNF-$\alpha$ ($P = 0.030$) after adjusting for the covariates (S1 Table).

**Discussion**

Gastrointestinal complications and persistent immune activation are some of the key pathologies of HIV infection [18, 25]. PLWH are also predisposed to risk factors that may exacerbate these problems, such as substance abuse [28]. In this study, we examined markers of gut permeability, microbial translocation, immune activation and inflammation in the context of cocaine use among PLWH who were on stable ART and virally suppressed. Cocaine users – identified via self-report, urine drug screen, and BE in blood – exhibited greater gut integrity damage and microbial translocation than cocaine non-users, as evidenced by higher levels of I-FABP and LPS, respectively. We also found associations between cocaine use and markers of immune activation, although the results were less consistent. Our data therefore suggest that cocaine use may exacerbate HIV-related microbial translocation and immune activation. These findings emphasize that strategies to prevent, identify, and treat substance use disorders among PLWH are needed and may aid in decreasing the high disease burden in this vulnerable population.

To the best of our knowledge, this is the first study showing direct associations of cocaine use with gut permeability and microbial translocation among PLWH. For example, Volpe et al. [33] did not detect any differences in LPS or sCD14 levels by HIV status or cocaine use,

**Table 3. Associations between cocaine use, gut integrity damage, microbial translocation and immune activation.**

| Variable | I-FABP* | LPS* | sCD14* | sCD27* | sCD163* |
|----------|---------|------|--------|--------|---------|
|          | B | SD | t    | P  | B | SD | t    | P  | B | SD | t    | P  | B | SD | t    | P  |
| Cocaine use | 0.24 | 0.11 | 2.17 | 0.033 | 0.39 | 0.11 | 3.88 | <0.001 | 0.02 | 0.11 | 0.19 | 0.850 | 0.08 | 0.09 | 0.89 | 0.371 | 0.44 | 0.16 | 2.65 | 0.010 |
| I-FABP*   | 0.12 | 0.11 | 1.05 | 0.296 | -0.13 | 0.10 | -1.15 | 0.252 | 0.16 | 0.08 | 1.48 | 0.142 | 0.02 | 0.15 | 0.24 | 0.808 |
| LPS*      | -0.12 | 0.09 | -1.07 | 0.285 | -0.01 | 0.07 | -0.14 | 0.866 | -0.09 | 0.14 | -0.84 | 0.401 |

**Bold** indicates statistical significance at $P < 0.05$.

* Estimates are adjusted for age, sex, race, CD4 cell count, suppressed HIV viral load (20–200 copies/mL), and cigarette smoking.

b Log-transformed

https://doi.org/10.1371/journal.pone.0275675.t003

However, the association between cocaine use and sCD163 was statistically significant at $P = 0.010$ (Table 3). No significant associations were found between cocaine use and inflammatory markers hs-CRP ($P = 0.688$), TNF-$\alpha$ ($P = 0.433$) and IL-6 ($P = 0.456$) after adjusting for age, sex, race, CD4 cell count, suppressed HIV viral load (20–200 copies/mL) and cigarette smoking. However, LPS levels were significantly associated with hs-CRP ($P = 0.040$) and TNF-$\alpha$ ($P = 0.030$) after adjusting for the covariates (S1 Table).

**Discussion**

Gastrointestinal complications and persistent immune activation are some of the key pathologies of HIV infection [18, 25]. PLWH are also predisposed to risk factors that may exacerbate these problems, such as substance abuse [28]. In this study, we examined markers of gut permeability, microbial translocation, immune activation and inflammation in the context of cocaine use among PLWH who were on stable ART and virally suppressed. Cocaine users – identified via self-report, urine drug screen, and BE in blood – exhibited greater gut integrity damage and microbial translocation than cocaine non-users, as evidenced by higher levels of I-FABP and LPS, respectively. We also found associations between cocaine use and markers of immune activation, although the results were less consistent. Our data therefore suggest that cocaine use may exacerbate HIV-related microbial translocation and immune activation. These findings emphasize that strategies to prevent, identify, and treat substance use disorders among PLWH are needed and may aid in decreasing the high disease burden in this vulnerable population.

To the best of our knowledge, this is the first study showing direct associations of cocaine use with gut permeability and microbial translocation among PLWH. For example, Volpe et al. [33] did not detect any differences in LPS or sCD14 levels by HIV status or cocaine use,

**Table 4. Logistic regression analysis predicting the likelihood of high levels of gut integrity damage and microbial translocation in cocaine users living with HIV.**

| Variable | Cocaine Users* |
|----------|---------------|
|          | Unadjusted OR (95% CI) | P-value | Adjusted OR* (95% CI) | P-value |
| I-FABP (pg/mL) | | | | |
| Above median (≥ 2460.43) | 2.69 (0.94–5.11) | 0.069 | 2.20 (0.89–5.45) | 0.087 |
| LPS (EU/mL) | | | | |
| Above median (≥ 0.63) | 4.86 (1.95–12.1) | 0.001 | 5.15 (1.89–13.9) | 0.001 |

**Bold** indicates statistical significance at $P < 0.05$.

* Reference category non-cocaine users

b Estimates are adjusted for age, sex, race, CD4 cell count, suppressed HIV viral load (20–200 copies/mL), and cigarette smoking.

https://doi.org/10.1371/journal.pone.0275675.t004
possibly due to a small sample size (N = 32). That said, MASH participants in this study showed similar I-FABP [38–41] and LPS [42–44] levels to the ones reported in other studies conducted in PLWH. Importantly, PLWH display higher concentrations of I-FABP compared to HIV-uninfected peers [38]. Our data show that cocaine users had higher levels of I-FABP and LPS than cocaine non-users. Thus, cocaine use may exacerbate gut permeability and subsequent microbial translocation in PLWH. Interestingly, levels of I-FABP in plasma did not correlate significantly with LPS, sCD14, or sCD163, although others have reported these associations [38]. A novel finding from this study was that cocaine users were 5.15 times more likely to exhibit high microbial translocation levels than non-users, which indicates the damaging effect of cocaine on the GI mucosa.

HIV has been shown to directly affect the enterocytes due to the action of its accessory protein Transactivation of transcription (Tat) that inhibits the uptake of glucose into the enterocyte. In addition, the envelope glycoprotein gp120, promotes calcium accumulation inside the cell affecting the ionic homeostasis [45, 46], and activates the intestinal immune system with the release of pro-inflammatory cytokines [47, 48]. Also, there is a massive loss of CD4+ T cells in the GI lamina propria. This loss also affects the CD4+ T helper 17 cells in the intestine, which are responsible for the intestinal homeostasis, and mucosal regeneration and integrity [2, 3].

Cocaine use has been associated with several gastrointestinal disturbances including diarrhea, nausea, vomiting, and anorexia [33], but mechanisms underlying the impact of cocaine on the gastrointestinal system have not been completely elucidated. While cocaine itself has a relatively short half-life, usually in the range of a few hours, its metabolites remain significantly longer in the circulation [49, 50]. Further, chronic cocaine use extends its half-life, prolonging its elimination from the body [49, 50]. Cocaine may lead to dysbiosis of the gut microbiome and also appears to have the ability to dysregulate the expression of tight junction proteins in the intestinal epithelium, promoting gut permeability of toxic microbial products and subsequent inflammatory response [34, 35]. Thus, the damaging effects of HIV on the enterocytes, the loss of intestinal CD4+ T cells and the likely role of cocaine in the disruption of gut barrier and increased permeability may indicate that cocaine and HIV seem to simultaneously compromise gut homeostasis and further promote microbial translocation. Our data showed that levels of BE in blood correlated with levels of sCD14 and sCD163, suggesting that cocaine metabolites promote immune activation while they remain in blood. However, we did not observe a significant association between cocaine and sCD14 and sCD27 immune activation and inflammatory markers in the regression analyses. It is important to reiterate that all our participants in this study were on stable ART (>6 months), suppressed viral load (<200 copies/mL), more than half had undetectable HIV viral load (<20 copies/mL), had CD4+ cell count >200 cells/μL, and did not report hazardous drinking (AUDIT score >8). These results indicate that cocaine may directly destabilize gut integrity as evidenced by the association between cocaine use, I-FABP and LPS. In addition, cocaine use was related to immune activation as shown by significant associations with sCD163.

This study had several important strengths, including the inclusion/exclusion criteria, which allowed us to isolate the effect of cocaine use in the context of HIV disease. Indeed, substance use is a risk factor for HIV disease progression [29, 51, 52]. We have previously shown that cocaine use can accelerate HIV disease progression by reducing adherence to HIV treatment, as well as through physiological mechanisms independent of ART adherence [29, 53]. In addition we used urine drug screen and determined cocaine metabolites in blood to strengthen the self-reported data on cocaine use, although even these biomarkers provide a relatively short window of detection [49]. Several limitations of this study should be acknowledged. Due to the eligibility criteria, the results of this study are mainly applicable to PLWH who are virally
suppressed and do not exhibit hazardous alcohol consumption patterns. Further, lack of HIV-uninfected participants prevents us from ascertaining how the impact of cocaine differs in PLWH from those uninfected with HIV. To the best of our knowledge, the impact of cocaine on microbial translocation and immune activation has not been examined outside of the context of HIV. Other biomarkers to assess gut permeability including tight junction proteins (occludin, zonulin, etc.), and Regenerating islet-derived protein 3 (REG3α) [8, 54–56] have not been determined in this study. However, LPS employed in this study is a widely used marker of microbial translocation, while I-FABP has been used as a marker of gut permeability in other studies with PLWH [38–41]. Longitudinal studies are needed since the cross-sectional design of this study prevents any determination of a temporal or causative association. Future studies should include participants who use and do not use cocaine, as well as people uninfected with HIV, as this may elucidate the specific changes in gut permeability, microbial translocation, immune activation and inflammation associated with cocaine use in PLWH.

Conclusions
Cocaine use is considered a relevant factor that accelerates HIV disease progression and promotes mortality among PLWH. The findings of this study suggest that cocaine use is associated with a loss of gut integrity and increased microbial translocation and immune activation in PLWH despite ART use and viral suppression. Thus, cocaine appears to have profound effects on both the gastrointestinal tract and the immune system. Further research with longitudinal design is needed in order to elucidate mechanisms behind the effects of cocaine on gut health and immunity in the context of HIV infection. This study provides important data to aid in the development of effective approaches that target lifestyle modifications and treatment for substance use disorders to decrease the burden of disease among PLWH.

Supporting information
S1 Table. Associations between cocaine use, gut integrity damage, microbial translocation and inflammation. Bold indicates statistical significance at $P < 0.05$. a Estimates are adjusted for age, sex, race, CD4 cell count, suppressed HIV viral load (20–200 copies/mL), and cigarette smoking. b Log-transformed.

S1 Dataset.

Acknowledgments
We would like to thank the study participants for their time; this study would not be possible without them. We are also grateful to the MASH Cohort Research Group for their contribution during data collection.

Author Contributions
Conceptualization: Jacqueline Hernandez, Javier A. Tamargo, Sabrina Sales Martinez, Adriana Campa, Marianna K. Baum.

Data curation: Jacqueline Hernandez, Javier A. Tamargo, Haley R. Martin, Kenneth E. Sherman.

Formal analysis: Jacqueline Hernandez, Javier A. Tamargo, Shenghan Lai.
Funding acquisition: Adriana Campa, Marianna K. Baum.
Investigation: Jacqueline Hernandez, Adriana Campa, Kenneth E. Sherman, Susan D. Rouster, Heidi L. Meeds, Marianna K. Baum.
Methodology: Jacqueline Hernandez, Kenneth E. Sherman, Susan D. Rouster, Heidi L. Meeds.
Project administration: Marianna K. Baum.
Resources: Sabrina Sales Martinez, Adriana Campa, Marianna K. Baum.
Supervision: Sabrina Sales Martinez, Adriana Campa, Marianna K. Baum.
Validation: Kenneth E. Sherman, Susan D. Rouster, Heidi L. Meeds.
Writing – original draft: Jacqueline Hernandez, Adriana Campa.
Writing – review & editing: Jacqueline Hernandez, Javier A. Tamargo, Sabrina Sales Martinez, Haley R. Martin, Rafick-Pierre Sékaly, Rebeka Bordi, Jag H. Khalsa, Raul N. Mandler.

References
1. Brown D, Mattapalli JJ. Gastrointestinal Tract and the Mucosal Macrophage Reservoir in HIV Infection. Clin Vaccine Immunol 2014; 21:1469–73. https://doi.org/10.1128/CVI.00518-14 PMID: 25185575
2. Blaschitz C, Raffatellu M. Th17 Cytokines and the Gut Mucosal Barrier. J Clin Immunol 2010; 30:196–203. https://doi.org/10.1007/s10875-010-9368-7 PMID: 20127275
3. Dillon SM, Lee EJ, Kotter C V, Austin GL, Dong Z, Hecht DK, et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol 2014; 7:983–94. https://doi.org/10.1038/mi.2013.116 PMID: 24399150
4. Guadalupe M, Sankaran S, George MD, Reay E, Verhoeven D, Shacklett BL, et al. Viral Suppression and Immune Restoration in the Gastrointestinal Mucosa of Human Immunodeficiency Virus Type 1-Infected Patients Initiating Therapy during Primary or Chronic Infection. J Virol 2006; 80:8236–47. https://doi.org/10.1128/JVI.00120-06 PMID: 16873279
5. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200:761–70. https://doi.org/10.1084/jem.20041196 PMID: 15365095
6. Miao YM, Hayes PJ, Gotch FM, Barrett MC, Francis ND, Gazzard BG. Elevated Mucosal Addressin Cell Adhesion Molecule-1 Expression in Acquired Immunodeficiency Syndrome Is Maintained during Antiretroviral Therapy by Intestinal Pathogens and Coincides with Increased Duodenal CD4 T Cell Densities. J Infect Dis 2002; 185:1043–50. https://doi.org/10.1086/340235 PMID: 11930313
7. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, et al. Intestinal permeability—a new target for disease prevention and therapy. BMC Gastroenterol 2014; 14:189. https://doi.org/10.1186/s12876-014-0189-7 PMID: 25407511
8. Schoultz I, Keita A V. The Intestinal Barrier and Current Techniques for the Assessment of Gut Permeability. Cells 2020; 9. https://doi.org/10.3390(cells9081909 PMID: 32824536
9. Mutlu EA, Keshavarzian A, Losurdo J, Swanson G, Siewe B, Forsyth C, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog 2014; 10:e1003829. https://doi.org/10.1371/journal.ppat.1003829 PMID: 24586144
10. Dinh DM, Volpe GE, Duffalo C, Bhalchandra S, Tai AK, Kane A V, et al. Intestinal Microbiota, Microbial Translocation, and Systemic Inflammation in Chronic HIV Infection. J Infect Dis 2015; 211:19–27. https://doi.org/10.1093/infdis/jiu408 PMID: 25057045
11. Dubourg G, Lagier JC, Hüb S, Sarenaud M, Bachar D, Robert C, et al. Gut microbiota associated with HIV infection is significantly enriched in bacteria tolerant to oxygen. BMJ Open Gastroenterol 2016; 3. https://doi.org/10.1136/bmjgast-2016-000060 PMID: 27547442
12. Vujkovic-Cvijin I, Sortino O, Verheij E, Sklar J, Wit FW, Kootstra NA, et al. HIV-associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseases. Nat Commun 2020; 11. https://doi.org/10.1038/s41467-020-16222-6 PMID: 32415070
13. Sortino O, Panunphak N, Schuetz A, Ortiz AM, Chomchey N, Belkaid Y, et al. Impact of Acute HIV Infection and Early Antiretroviral Therapy on the Human Gut Microbiome. Open Forum Infect Dis 2020; 7. https://doi.org/10.1093/ofid/ofz367 PMID: 33324725
Cocaine use associated gut permeability and microbial translocation in PLWH in the MASH cohort

Ishizaka A, Koga M, Mizutani T, Parbie PK, Prawisud a D, Yusa N, et al. Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation. Microbiol Spectr 2021; 9. https://doi.org/10.1128/Spectrum.00708-21 PMID: 3439849

15. Pérez-Santiago J, Marquine MJ, Cookson D, Giraud-Colón R, Heaton RK, Grant I, et al. Gut microbiota dysbiosis is associated with worse emotional states in HIV infection. J Neurovirol 2021;27. https://doi.org/10.1007/s13365-020-00933-1 PMID: 33651324

16. Marchetti G, Tincati C, Silvestri G. Microbial Translocation in the Pathogenesis of HIV Infection and AIDS. Clin Microbiol Rev 2013; 26:2–18. https://doi.org/10.1128/CMR.00050-12 PMID: 23297256

17. Zevin A, McKinnon L, Burgener A, Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2013; 21:6–13. https://doi.org/10.1016/j.tim.2012.09.001 PMID: 23062765

18. Price DA, Kazzaz Z, Asher TE, Bornstein E, Lederman MM, Deeks SG, et al. Microbial translocation is independently predict mortality in HIV infection. J Infect Dis 2011; 203:780–90. https://doi.org/10.1093/infdis/iqj118 PMID: 21252259

19. Walle MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, Hou W, et al. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 2010; 24. https://doi.org/10.1097/QAD.0b013e328339e228 PMID: 20559035

20. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One 2008; 3:e1915. https://doi.org/10.1371/journal.pone.0001915 PMID: 18382686

21. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2013; 21:6–13. https://doi.org/10.1016/j.tim.2012.09.001 PMID: 23062765

22. Paranjape RS. Immunopathogenesis of HIV infection. Indian J Med Res 2005; 12:1365–71. https://doi.org/10.1038/mn1511 PMID: 17115046

23. Sandler NG, Wand H, Hoque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780–90. https://doi.org/10.1093/infdis/iqj118 PMID: 21252259

24. Tincati C, Bellisri GM, Ancona G, Merlili E, d’Arminio Monforte A, Marchetti G. Role of In Vitro Stimulation with Lipopolysaccharide on T-Cell Activation in HIV-Infected Antiretroviral-Treated Patients. Clin Dev Immunol 2012; 2012:935425. https://doi.org/10.1155/2012/935425 PMID: 22400042

25. Sokoya T, Steel HC, Nieuwoudt M, Rossouw TM. HIV as a Cause of Immune Activation and Immunosence. Mediators Inflamm 2017; 2017:6825493. https://doi.org/10.1155/2017/6825493 PMID: 29209103

26. Klatt NR, Chomont N, Dorek DC, Deeks SG. Immune Activation And HIV Persistence: Implications For Curative Approaches To HIV Infection. Immunol Rev 2013; 254:326–42. https://doi.org/10.1111/imr.12065 PMID: 23772629

27. SAMSMA. Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. HHS Publ No PEP19-5068, NSDUH Ser H-54 2019;170.

28. Shiau S, Arpadi SM, Yin MT, Martin N. Patterns of drug use and HIV infection among adults in a nationally representative sample. Addict Behav 2017; 68. https://doi.org/10.1016/j.addbeh.2017.01.015 PMID: 28088742

29. Baum M, Rafie C, Lai S, Sales S, Page B, Campbell J. Crack-Cocaine Use Accelerates HIV Disease Progression in a Cohort of HIV-Positive Drug Users. JAIDS J Acquir Immune Defic Syndr 2009; 50:93–9. https://doi.org/10.1097/QAI.0b013e3181900129 PMID: 19295339

30. Lucas GM, Atta MG, Fine DM, McFall AM, Estrella MM, Zook K, et al. HIV, Cocaine Use, and Hepatitis C Virus: A Triad of Nontraditional Risk Factors for Subclinical Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2016. https://doi.org/10.1161/ATVBAHA.116.307985 PMID: 27609369

31. Cregler LL. Adverse health consequences of cocaine abuse. J Natl Med Assoc 1989; 81:27–38.

32. Gibbons TE, Sayed K, Fuchs GJ. Massive pan-gastrointestinal bleeding following cocaine use. World J Pediatr 2009; 5:149–51. https://doi.org/10.1007/s12519-009-0030-5 PMID: 19715540

33. Volpe GE, Ward H, Mwamburi M, Dinh D, Bhalchandra S, Zook K, et al. Associations of cocaine use and HIV infection with the intestinal microbiota, microbial translocation, and Inflammation. J Stud Alcohol Drugs 2014; 75:347–57. https://doi.org/10.15288/jsad.2014.75.347 PMID: 24650829

34. Chivero ET, Ahmad R, Thangaraj A, Periyasamy P, Kumar B, Kroege E, et al. Cocaine Induces Inflammatory Gut Milieu by Compromising the Mucosal Barrier Integrity and Altering the Gut Microbiota Composition. Sci Rep 2019; 9:12187. https://doi.org/10.1038/s41598-019-48428-2 PMID: 31434922

35. Scorza C, Piccini C, Martinez Busi M, Abin Carriquiri JA, Zunino P. Alterations in the Gut Microbiota of Rats Chronically Exposed to Volatilized Cocaine and Its Active Adulterants Caffeine and Phenacetin. Neurotox Res 2019; 35. https://doi.org/10.1007/s12640-018-9936-9 PMID: 30066173
36. Chen X, Zheng X, Zhan M, Zhou Z, Zhan CG, Zheng F. Metabolic Enzymes of Cocaine Metabolite Benzoylecgonine. ACS Chem Biol 2016; 11. https://doi.org/10.1021/acscchembio.6b00277 PMID: 27224254

37. Snozek CLH, Bjergum MW, Langman LJ. Cocaine and metabolites by LC-MS/MS. Methods Mol Biol 2012; 902. https://doi.org/10.1007/978-1-61779-934-1_8 PMID: 22767110

38. Cheru LT, Park EA, Saylor CF, Burdo TH, Fitch KV, Looby S, et al. I-FABP is higher in people with chronic HIV than elite controllers, related to sugar and fatty acid intake and inversely related to body fat in people with HIV. Open Forum Infect Dis 2018; 5. https://doi.org/10.1093/öffd/ofy288 PMID: 30515430

39. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. J Infect Dis 2014; 210:1228–38. https://doi.org/10.1093/infdis/jiu238 PMID: 24755434

40. Skowrya A, Mikula T, Suchacz M, Skowrya A, Wierciński-Drapalo A. The role of serum I-FABP concentration in assessment of small intestine mucosa among HIV-infected patients. Eur J Inflamm 2015; 13:75–81. https://doi.org/10.1177/1721727X15586660

41. De Oliveira Feitosa De Castro F, Silva JM, Doreneas GP, De Sousa Barros JB, Ribeiro CB, Noronha I, et al. Distinct inflammatory profiles in HIV-infected individuals under antiretroviral therapy using cannabis, cocaine or cannabis plus cocaine. AIDS 2019; 33:1831–42. https://doi.org/10.1097/QAD.00000000000002296 PMID: 31490211

42. Luo Z, Heath SL, Li M, Yang H, Wu Y, Collins M, et al. Variation in Blood Microbial Lipopolysaccharide (LPS) Contributes to Immunoreconstitution in Response to Suppressive Antiretroviral Therapy in HIV. SSRN Electron J 2021. https://doi.org/10.2139/ssrn.3980526

43. Pedro MN, Magro DO, Da Silva EUPP, Guadagnini D, Santos A, De Jesus Pedro R, et al. Plasma levels of lipopolysaccharide correlate with insulin resistance in HIV patients. Diabetol Metab Syndr 2018; 10. https://doi.org/10.1186/s13098-018-0308-7 PMID: 29434676

44. Ouyang J, Isnard S, Lin J, Fombuena B, Chatterjee D, Wiche Salinas TR, et al. Daily variations of gut microbial translocation markers in ART-treated HIV-infected people. AIDS Res Ther 2020;17. https://doi.org/10.1186/s12981-020-00273-4 PMID: 32398104

45. Canani RB, De Marco G, Passariello A, Buccigrossi V, Ruotolo S, Bracale I, et al. Inhibitory effect of HIV-1 Tat protein on the sodium-D-glucose symporter of human intestinal epithelial cells. AIDS 2006; 20:5–10. https://doi.org/10.1097/01.aids.0000198088.85572.68 PMID: 16327313

46. Maresca M, Mahloud R, Garry N, Kotler DP, Fantini J, Clayton F. The Virotoxin Model of HIV-1 Enteropathy: Involvement of GPR15/Bob and Galactosylceramide in the Cytopathic Effects Induced by HIV-1 gp120 in the HT-29-D4 Intestinal Cell Line. J Biomed Sci 2003; 10:156–66. https://doi.org/10.1007/BF02256007 PMID: 12566994

47. MacDonald TT, Spencer J. The Role of Activated T Cells in Transformed Intestinal Mucosa. Digestion 1990; 46:290–6. https://doi.org/10.1159/000200399 PMID: 2262061

48. Ciccocioppo R, Di Sabatino A, Parroni R, Muzi P, D’Alò S, Ventura T, et al. Increased enterocyte apoptosis and Fas-Fas ligand system in celiac disease. Am J Clin Pathol 2001; 115:494–503. https://doi.org/10.1309/UV54-BHP3-A66B-0QUD PMID: 11293896

49. Jufer RA, Wstadik A, Walsh SL, Levine BS, Cone EJ. Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. J Anal Toxicol 2000; 24. https://doi.org/10.1093/jat/24.7.467 PMID: 11043648

50. Moolchan ET, Cone EJ, Wstadik A, Huestis MA, Preston KL. Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: Plasma and saliva analysis. J Anal Toxicol 2000; 24. https://doi.org/10.1093/jat/24.7.458 PMID: 11043647

51. Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses 2010; 26. https://doi.org/10.1089/aid.2009.0211 PMID: 20455765

52. Degarege A, Krupp K, Tamargo J, Martinez SS, Campa A, Baum M. Polysubstance use and adherence to antiretroviral treatment in the Miami Adult Studies on HIV (MASH) cohort. AIDS Care 2021. https://doi.org/10.1080/09540121.2021.1896660 PMID: 33663276

53. Rafie C, Campa A, Smith S, Huffman F, Newman F, Baum MK. Cocaine Reduces Thymic Endocrine Function: Another Mechanism for Accelerated HIV Disease Progression. AIDS Res Hum Retroviruses 2011; 27:815–22. https://doi.org/10.1089/AID.2010.0086 PMID: 21142650

54. Isnard S, Ramendra R, Dupuy FP, Lin J, Fombuena B, Kokinov N, et al. Plasma Levels of C-Type Lectin REG3α and Gut Damage in People With Human Immunodeficiency Virus. J Infect Dis 2020; 221. https://doi.org/10.1093/infdis/jiz423 PMID: 31504638
55. Tyszka M, Biliński J, Basak GW. Advances in intestinal barrier preservation and restoration in the allogeneic hematopoietic cell transplantation setting. J Clin Med 2021; 10. https://doi.org/10.3390/jcm10112508 PMID: 34204044

56. Vanuytsel T, Tack J, Farre R. The Role of Intestinal Permeability in Gastrointestinal Disorders and Current Methods of Evaluation. Front Nutr 2021; 8. https://doi.org/10.3389/fnut.2021.717925 PMID: 34513903